| January 30, 2014 | ISSUE NUMBER 336 VOL 1 |
BRIC Markets
Russia’s Bet on Biopharma
Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector, writes William Looney ...Read more
Social Media & Marketing
On-Demand Marketing Re-Invents Customer Relationships
Staying on top of the marketing information stream can be difficult for your customers, but plans for a ‘holistic’ healthcare network could make relationships easier to manage, writes Peter Houston ...Read more
ZS Associates – Striking the Right Balance between Data Stewards and Data Automation
There’s no silver bullet for transforming data quality management from problem into competitive advantage. But a structured approach that considers  the right combination of human judgment and automation will yield significant improvements that are sustainable over the long term.
Global
Read the New Pharm Exec Global Digest — Regulatory Special
In this month’s Pharm Exec Global Digest — Regulating Cloud Computing; Regulators’ Three Goals for 2014; the European Regulatory Outlook; Obamacare and the US’s ‘New Medical Culture’’ and more ...Read more
Patent Cliff
Biosimilars or Bust
Where are the biosimilars to help cut costs as the first wave of biologics, or complex, small molecule respiratory drugs, for example, go off patent? They've arrived in Europe, but the U.S. lags ...Read more
AndaMEDS is a division of Anda Inc., a leading national distributor of pharmaceuticals
AndaMEDS offers a broad selection of vaccines, specialty injectables and medications administered in physicians' offices. Established in 1995, we service thousands of physician practices and create targeted marketing and customized distribution services for our manufacturer partners. www.andameds.com
Outlook
Pharm Exec’s Annual Industry Outlook 2014
For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. As our annual industry outlook confirms, it’s time to be decisive — muddling through is so ‘yesterday’ ...Read more
|
|
|
|
 //Merck KGaA shares fell as much as 12 per cent in response to the unexpected departure of Chief Financial Officer Matthias Zachert.//Sorbent Therapeutics, Inc. (Sunnyvale, CA) announced that Tom O’Neil has joined the company as Chief Financial Officer.//Neurotrope, Inc. (Plantation, FL) hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations, and Mr. David Crockford as Vice President, Regulatory Affairs.//Gilead Sciences, Inc. (Foster City, CA) announced several promotions within the company’s senior management team. Robin Washington, Chief Financial Officer was promoted to Executive Vice President; Paul Carter, formerly Senior Vice President, International Commercial Operations, was promoted to Executive Vice President with responsibility for Gilead’s worldwide commercial organization; and John McHutchison, MD, formerly Senior Vice President, Liver Disease Therapeutics, becomes Executive Vice President and will assume additional responsibility for clinical development programs in the areas of oncology, respiratory diseases and inflammation.// |
|
|
|
|
|
 |
|
|
|
| |
|
| |
|
 |
|
 |
What in your opinion is the greatest opportunity for industry over the next five years?
|
|
|
|
